Literature DB >> 18429990

Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis.

Tung-Ming Leung1, George L Tipoe, Emily C Liong, Thomas Y H Lau, Man-Lung Fung, Amin A Nanji.   

Abstract

Reduced expression of endothelial nitric oxide synthase (eNOS) in chronic liver disease can reduce hepatic perfusion and accelerate fibrosis. The relationship between eNOS expression and liver fibrogenesis remains unclear. We investigated whether L-arginine attenuated chronic liver fibrosis through eNOS expression. Chronic liver injury was induced by administration of carbon tetrachloride (CCl(4)) to mice for 8 weeks. 5-Methylisothiourea hemisulphate (SMT), an iNOS inhibitor, or L-arginine, a NOS substrate were injected subcutaneously. CCl(4)-induced hepatotoxicity, oxidative stress and accumulation of collagen were detected in the liver. The expression levels of inducible NOS (iNOS) and nuclear factor kappa-B (NF-kappaB) activity in the liver after CCl(4) treatment were increased but eNOS expression and activator protein-1 (AP-1) activity were decreased. Both SMT and L-arginine effectively reduced CCl(4) induced oxidative stress and collagen formation, but L-arginine showed a significantly greater suppression of collagen formation, iNOS expression and NF-kappaB activity. L-arginine also restored the level of eNOS and AP-1 activity. L-arginine was more effective than SMT in suppressing liver fibrosis. L-arginine might improve NO production which facilitates hepatic blood flow and thus retards liver fibrogenesis. Our results showed that the reduced eNOS expression in CCl(4)-treated mice was reversed by L-arginine. Furthermore, L-arginine also reversed the reduced AP-1 activity, an eNOS promoter.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18429990      PMCID: PMC2525781          DOI: 10.1111/j.1365-2613.2008.00590.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  43 in total

1.  NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension.

Authors:  S Fiorucci; E Antonelli; O Morelli; A Mencarelli; A Casini; T Mello; B Palazzetti; D Tallet; P del Soldato; A Morelli
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

2.  Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat.

Authors:  Xu Li; Ying Meng; Pingsheng Wu; Zhenshu Zhang; Xishan Yang
Journal:  Regul Pept       Date:  2006-09-12

3.  Effects of L-arginine on the systemic, mesenteric, and hepatic circulation in patients with cirrhosis.

Authors:  S Kakumitsu; H Shijo; M Yokoyama; T Kim; N Akiyoshi; K Ota; K Kubara; M Okumura; K Inoue
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

Review 4.  The basics about nitric oxide.

Authors:  Richard Bruckdorfer
Journal:  Mol Aspects Med       Date:  2005-01-24

Review 5.  The role of vasoactive mediators in portal hypertension.

Authors:  J C García-Pagán; J Bosch; J Rodés
Journal:  Semin Gastrointest Dis       Date:  1995-07

6.  Experimental model of hepatic fibrosis following repeated periportal necrosis induced by allylalcohol.

Authors:  S A Jung; Y H Chung; N H Park; S S Lee; J A Kim; S H Yang; I H Song; Y S Lee; D J Suh; I H Moon
Journal:  Scand J Gastroenterol       Date:  2000-09       Impact factor: 2.423

Review 7.  Role of nitric oxide in inflammation.

Authors:  F S Laroux; K P Pavlick; I N Hines; S Kawachi; H Harada; S Bharwani; J M Hoffman; M B Grisham
Journal:  Acta Physiol Scand       Date:  2001-09

Review 8.  Nitric oxide, cell signaling and cell death.

Authors:  Gilbert A Blaise; Dominique Gauvin; Marius Gangal; Simon Authier
Journal:  Toxicology       Date:  2005-03-15       Impact factor: 4.221

9.  Differential expression and localization of nitric oxide synthases in cirrhotic livers of bile duct-ligated rats.

Authors:  Chang-Li Wei; Hoon-Eng Khoo; Kang-Hoe Lee; Wei-Min Hon
Journal:  Nitric Oxide       Date:  2002-09       Impact factor: 4.427

10.  Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expression in fulminant hepatic failure.

Authors:  Ludger Leifeld; Magdalene Fielenbach; Franz-Ludwig Dumoulin; Nicola Speidel; Tilman Sauerbruch; Ulrich Spengler
Journal:  J Hepatol       Date:  2002-11       Impact factor: 25.083

View more
  16 in total

1.  In Vivo engineering of the vocal fold ECM with injectable HA hydrogels-late effects on tissue repair and biomechanics in a rabbit model.

Authors:  Susan L Thibeault; Sarah A Klemuk; Xia Chen; Beatriz H Quinchia Johnson
Journal:  J Voice       Date:  2010-04-24       Impact factor: 2.009

2.  Enteral arginine modulates inhibition of AP-1/c-Jun by SP600125 in the postischemic gut.

Authors:  Kechen Ban; Rachel Santora; Rosemary A Kozar
Journal:  Mol Cell Biochem       Date:  2010-10-29       Impact factor: 3.396

3.  Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?

Authors:  Yusuf Yilmaz
Journal:  World J Hepatol       Date:  2012-12-27

4.  S-allylmercaptocysteine reduces carbon tetrachloride-induced hepatic oxidative stress and necroinflammation via nuclear factor kappa B-dependent pathways in mice.

Authors:  Jia Xiao; Emily C Liong; Ming-Tat Ling; Yick-Pang Ching; Man-Lung Fung; George L Tipoe
Journal:  Eur J Nutr       Date:  2011-06-18       Impact factor: 5.614

5.  Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.

Authors:  Resat Cinar; Malliga R Iyer; Ziyi Liu; Zongxian Cao; Tony Jourdan; Katalin Erdelyi; Grzegorz Godlewski; Gergő Szanda; Jie Liu; Joshua K Park; Bani Mukhopadhyay; Avi Z Rosenberg; Jeih-San Liow; Robin G Lorenz; Pal Pacher; Robert B Innis; George Kunos
Journal:  JCI Insight       Date:  2016-07-21

6.  Effect of S-methylisothiourea in acetaminophen-induced hepatotoxicity in rat.

Authors:  Amar S More; Rashmi R Kumari; Gaurav Gupta; Kandasamy Kathirvel; Milindmitra K Lonare; Rohini S Dhayagude; Dhirendra Kumar; Dinesh Kumar; Anil K Sharma; Surendra K Tandan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-08-11       Impact factor: 3.000

7.  Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage.

Authors:  Yueming Tang; Christopher B Forsyth; Ashkan Farhadi; Jayanthi Rangan; Shriram Jakate; Maliha Shaikh; Ali Banan; Jeremy Z Fields; Ali Keshavarzian
Journal:  Alcohol Clin Exp Res       Date:  2009-04-09       Impact factor: 3.455

8.  Xenon computed tomography can evaluate the improvement of hepatic hemodynamics before and after endoscopic injection sclerotherapy.

Authors:  Hideaki Takahashi; Michihiro Suzuki; Ryuta Shigefuku; Miki Okano; Tetsuya Hiraishi; Rei Takagi; Yohei Noguchi; Nobuhiro Hattori; Moriaki Hatsugai; Kazunari Nakahara; Masaru Okamoto; Minoru Kobayashi; Hiroki Ikeda; Yasunobu Fukuda; Yoshihiko Nagase; Toshiya Ishii; Kotaro Matsunaga; Nobuyuki Matsumoto; Chiaki Okuse; Shigeru Sase; Fumio Itoh
Journal:  J Gastroenterol       Date:  2013-02-09       Impact factor: 7.527

9.  Nitric oxide augments mesenchymal stem cell ability to repair liver fibrosis.

Authors:  Gibran Ali; Sadia Mohsin; Mohsin Khan; Ghazanfar Ali Nasir; Sulaiman Shams; Shaheen N Khan; Sheikh Riazuddin
Journal:  J Transl Med       Date:  2012-04-25       Impact factor: 5.531

10.  Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis.

Authors:  Wei Wang; Caiyan Zhao; Junying Zhou; Zhen Zhen; Yadong Wang; Chuan Shen
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.